Arcus Biosciences, Inc.
3928 Point Eden Way, Hayward, CA 94545
1800 Sierra Point Parkway, Brisbane, CA 94005
191 articles about Arcus Biosciences, Inc.
Arcus Biosciences Announces Pricing of Initial Public Offering
Arcus Biosciences announced the pricing of its initial public offering of 8,000,000 shares of common stock at a price to the public of $15.00 per share for total gross proceeds of $120,000,000.
Arcus Biosciences Appoints David Beier to Board of Directors
Mr. Beier brings extensive experience in the biopharmaceutical industry, particularly in areas such as healthcare policy, government affairs, regulatory affairs, pricing, healthcare economics and product commercialization.
Sage Therapeutics Fills Its Pockets
11/27/2017Sage Therapeutics has been on a roll with good news lately.
Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing.
Bay Area Startup Arcus Biosciences Lands $307 Million+ Deal With Taiho Pharma
Arcus Biosciences Appoints Kate Falberg To Its Board Of Directors
Arcus Biosciences, Wuxi Biologics Hammer Out R&D Cancer Pact Worth $816 Million+
What You Need to Know About Arcus Biosciences
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
Taiho Ventures Invests In Arcus Biosciences As Part Of $70 Million Series B Investment Round
Bay Area Startup Arcus Biosciences Emerges With $120 Million